BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12794521)

  • 21. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study.
    Tsurusawa M; Watanabe T; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Sekimizu M; Koh K; Kosaka Y; Komada Y; Saito AM; Nakazawa A; Horibe K;
    Leuk Lymphoma; 2016 Jul; 57(7):1657-64. PubMed ID: 26694130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
    Larson RA; Dodge RK; Linker CA; Stone RM; Powell BL; Lee EJ; Schulman P; Davey FR; Frankel SR; Bloomfield CD; George SL; Schiffer CA
    Blood; 1998 Sep; 92(5):1556-64. PubMed ID: 9716583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial.
    Bennett CL; Hynes D; Godwin J; Stinson TJ; Golub RM; Appelbaum FR;
    Cancer Invest; 2001; 19(6):603-10. PubMed ID: 11486703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer.
    Riikonen P; Rahiala J; Salonvaara M; Perkkiö M
    Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer.
    Rahiala J; Perkkiö M; Riikonen P
    Med Pediatr Oncol; 1999 May; 32(5):326-30. PubMed ID: 10219332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia.
    Clarke V; Dunstan FD; Webb DK
    Med Pediatr Oncol; 1999 May; 32(5):331-5. PubMed ID: 10219333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.
    Goa KL; Bryson HM
    Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocyte colony-stimulating factor in neutropenic, pediatric solid tumor patients following chemotherapy.
    Ayan I; Kebudi R; Doğan S; Tokuç G; Görgün O
    Pediatr Hematol Oncol; 1996; 13(5):417-24. PubMed ID: 10897813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.
    Dranitsaris G; Altmayer C; Quirt I
    Pharmacoeconomics; 1997 Jun; 11(6):566-77. PubMed ID: 10173030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission.
    Kantarjian HM; Estey E; O'Brien S; Anaissie E; Beran M; Pierce S; Robertson L; Keating MJ
    Cancer; 1993 Nov; 72(10):2950-5. PubMed ID: 7693325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group.
    Alonzo TA; Kobrinsky NL; Aledo A; Lange BJ; Buxton AB; Woods WG
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):627-35. PubMed ID: 12439034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
    Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
    J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.